Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
• To compare the efficacy of the following 2 treatment paradigms in subjects who have achieved an inadequate (Investigator’s Global Assessment [IGA] ≥2) response to ustekinumab at Week 16: - Switching to guselkumab treatment. - Remaining on ustekinumab treatment. • To assess the safety and tolerability of guselkumab in subjects with moderate to severe plaque-type psoriasis and an inadequate (IGA≥2) response to ustekinumab at Week 16.
Inclusion criteria
- Moderate to severe plaque-type psoriasis